Eisai first quarter results story – correction
This article was originally published in Scrip
The title of the August 1st Scrip Online story on Eisai's first quarter results should have read: "MGI boost for Eisai, but rabeprazole languishes", not "MGI boost for Eisai but lansoprazole languishes". Rabeprazole should also have been substituted for lansoprazole in the fourth paragraph of the story, which referred to the development of over-the-counter versions of the product.
You may also be interested in...
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.